HAEMONETICS CORP/MASS (HAE:NYSE)
$57.34 -1.08 (-1.8487%)
Analysed HAEMONETICS CORP/MASS (HAE:NYSE) News Sources
1 Value Stock on Our Buy List and 2 Facing Headwinds
06-04-2026
yahoo.com
Haemonetics Sets Date for Publishing Fourth Quarter and Fiscal Year 2026 Results: May 7, 2026
01-04-2026
yahoo.com
Is It Time To Reassess Haemonetics (HAE) After Prolonged Share Price Weakness
01-04-2026
yahoo.com
GVS SpA (STU:4YQ) Q4 2025 Earnings Call Highlights: Strong Safety Division Growth Amidst Challenges
31-03-2026
yahoo.com
Haemonetics Receives FDA Approval for Expanded Labeling of the VASCADE MVP® XL Venous Vascular Closure System
30-03-2026
yahoo.com
3 Small-Cap Stocks That Fall Short
23-03-2026
yahoo.com
What Investors Should Know About a $24 Million Exit From a Medical Device Stock Down 9% This Past Year
20-03-2026
fool.com
Does Haemonetics' (HAE) Hospital Rebound and NexSys Expansion Reframe Its Competitive Positioning?
15-03-2026
yahoo.com
Why Is QuidelOrtho (QDEL) Down 24.5% Since Last Earnings Report?
13-03-2026
yahoo.com
2 Healthcare Stocks with Solid Fundamentals and 1 Facing Challenges
13-03-2026
yahoo.com
What is the current price of HAEMONETICS CORP/MASS (HAE:NYSE)?
The current price of HAEMONETICS CORP/MASS (HAE:NYSE) is $57.34.
HAEMONETICS CORP/MASS (HAE:NYSE) absolute price change since previous trading day?
The absolute price change of HAEMONETICS CORP/MASS (HAE:NYSE) since the previous trading day is $-1.08.
HAEMONETICS CORP/MASS (HAE:NYSE) percentage price change since previous trading day?
The percentage price change of HAEMONETICS CORP/MASS (HAE:NYSE) since the previous trading day is -1.8487%.
What is the most recent average sentiment score for HAEMONETICS CORP/MASS (HAE:NYSE)?
The most recent average sentiment score for HAEMONETICS CORP/MASS (HAE:NYSE) is 75 out of 100.
What is the most recent average sentiment for HAEMONETICS CORP/MASS (HAE:NYSE)?
The most recent sentiment for HAEMONETICS CORP/MASS (HAE:NYSE) is .
SEC-8K** Filing Available For HAEMONETICS CORP/MASS (HAE:NYSE)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.